# Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders
Canonical URL: https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-expands-intellectual-property-portfolio-with-new-u-s-patent-granted-for-genetic-based-treatment-of-alcohol-and-opioid-use-disorders
Ticker: ADIL
Company: Adial Pharmaceuticals
Source: Adial Pharmaceuticals
Published: 2025-05-01 08:30 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemSubheadDiv">New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use</div><div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p

## Article Body
New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use

GLEN ALLEN, Va., May  01, 2025  (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage...
## Recent Company News
- 2025-06-11 08:00 EST — [Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04](https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-advances-toward-phase-3-development-for-ad04) — Source: Adial Pharmaceuticals
- 2025-05-15 08:30 EST — [Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-business-update) — Source: Adial Pharmaceuticals
- 2025-05-13 08:30 EST — [Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study](https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-receives-milestone-payment-from-adovate-following-initiation-of-phase-1-study) — Source: Adial Pharmaceuticals
- 2025-05-08 08:30 EST — [Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration](https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration) — Source: Adial Pharmaceuticals
- 2025-05-02 11:48 EST — [Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds](https://biopharmsignal.com/news/ADIL/adial-pharmaceuticals-announces-a-warrant-inducement-transaction-for-2-75-million-in-gross-proceeds) — Source: Adial Pharmaceuticals
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)